News
-
-
-
COMMUNIQUÉ DE PRESSE
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
Tharimmune, Inc. appoints Prof. David Jones, an expert in autoimmune liver disease, to its Scientific Advisory Board. Prof. Jones brings valuable insights to advance lead drug candidate TH104 for PBC patients -
-
-
COMMUNIQUÉ DE PRESSE
Nextech3d.ai's 3D Assets Now Fully Compatible with Google Merchant Center and Manufacturer Center
Nextech3D.ai's 3D assets now compatible with Google Merchant Center, offering rich product visualization, enhanced customer engagement, seamless integration, and increased conversion rates for e-commerce. CEO Evan Gappelberg highlights the benefits of integrating 3D models -
COMMUNIQUÉ DE PRESSE
Secarna Pharmaceuticals publishes new data in Nucleic Acid Therapeutics showcasing strategies to detect and prevent immunostimulatory potential of LNA-modified ASOs
Secarna Pharmaceuticals publishes new data in Nucleic Acid Therapeutics highlighting strategies to detect and prevent immunostimulatory potential of LNA-modified ASOs -
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance
MIRA Pharmaceuticals reveals new promising preclinical data for Ketamir-2, a novel oral ketamine analog, indicating potential advantages for treating neurological and neuropsychiatric disorders
